How a $108 Million Loan Fuels the Next Wave of Cancer Treatment

Jan de Vries · 2026-08-31

There's a big push happening right now in European health tech, and a recent nine-figure loan is a perfect example. Stockholm-based medical technology leader Elekta just secured a massive financial boost from the European Investment Bank (EIB), the EU's main financing arm. We're talking about a loan of up to $108 million, converted from the original €100 million. This isn't just a random cash infusion. It's a strategic move that tells us a lot about where the EU is placing its bets for the future. ### The TechEU Program's Big Bet This financing comes directly from the EIB Group's TechEU program. Think of it as the EU's dedicated fund to make sure Europe doesn't fall behind in critical tech sectors. The goal is crystal clear: strengthen investment in strategic innovation and keep world-class companies innovating on European soil. It's part of a broader push around health research, competitiveness, and next-generation medical technology. As Karl Nehammer, Vice-President of the EIB, put it: “Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here.” He went on to say this financing is specifically aimed at supporting "the next generation of cancer and neurological treatments." ### What Elekta Plans to Do With the Funds So, what does a $108 million loan actually buy in the world of advanced medicine? For Elekta, it's about fueling a much larger research engine. The EIB loan will cover roughly half of a nearly $216 million research program the company has planned for the years 2026 through 2029. Most of this intensive R&D work will be anchored in their home bases in Sweden and the Netherlands. It's a significant commitment to a company with a long history. Founded back in 1972 by Lars and Laurent Leksell and now publicly traded on Nasdaq Stockholm, Elekta has built its reputation on precision radiation medicine. Their technology is used to treat a daunting list of conditions: - Various cancers, including brain, breast, kidney, lung, pancreatic, and prostate - Certain neurological disorders They've built their solutions around three core pillars: adaptive radiotherapy, precision treatment delivery, and integrated clinical workflows. The scale is staggering—their tech treats more than 2 million patients every single year. ### The Human and Business Impact With around 4,000 employees and a presence in over 40 countries, Elekta is a major global player. This financing is about maintaining that edge in a market where demand is only growing. Klara Eiritz, Elekta's Chief Financial Officer, connected the financial move directly to the on-the-ground reality for healthcare providers. “As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision,” she said. For her, this loan “provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience.” In practical terms, the money will back their work across several advanced therapy areas: - Radiotherapy - Radiosurgery - Brachytherapy - The crucial software platforms used to plan and deliver these complex treatments The ultimate aim is to improve treatment for a wide range of conditions, from brain and body tumors to essential tremor and specific forms of epilepsy. It's about making treatments more accurate, more efficient, and more accessible to a growing number of patients. ### A Signal of Broader EU Support This deal doesn't exist in a vacuum. It's part of a clear pattern. Just look at the numbers: in 2025 alone, the EIB Group signed a colossal $108 billion in new financing across more than 870 projects. Their priorities? Climate action, digitalization, security, and social infrastructure. The Elekta loan follows other recent EIB-backed moves in health tech, like a $21.6 million venture debt agreement with Finnish digital pathology firm Aiforia this past July. It's a signal that the EU is serious about backing its health tech champions. For professionals watching the European startup and incorporation landscape, deals like this are critical indicators. They show where institutional capital is flowing and which sectors are deemed strategic for long-term European competitiveness. When a publicly-traded MedTech veteran gets this level of support, it underscores a commitment to an entire ecosystem, not just flashy new startups. It's about building and sustaining the pillars of a modern, resilient European economy.